396 related articles for article (PubMed ID: 27022223)
1. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
4. Delayed-onset primary cytomegalovirus disease after liver transplantation.
Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Treatment Strategy After a Liver Transplant: Preemptive Therapy or Prophylaxis for Cytomegalovirus Seropositive Donor and Recipient.
Lindner K; Anthoni C; Beckebaum S; Senninger N; Hölzen JP; Wolters H
Exp Clin Transplant; 2016 Aug; 14(4):419-23. PubMed ID: 27506260
[TBL] [Abstract][Full Text] [Related]
7. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
8. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
9. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.
Sullivan T; Brodginski A; Patel G; Huprikar S
Transplantation; 2015 Apr; 99(4):855-9. PubMed ID: 25208322
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
11. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
12. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
14. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.
Scott GM; Naing Z; Pavlovic J; Iwasenko JM; Angus P; Jones R; Rawlinson WD
J Clin Virol; 2011 Aug; 51(4):229-33. PubMed ID: 21641274
[TBL] [Abstract][Full Text] [Related]
15. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
Razonable RR
World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.
Onor IO; Todd SB; Meredith E; Perez SD; Mehta AK; Marshall Lyon G; Knechtle SJ; Hanish SI
Transpl Int; 2013 Jun; 26(6):592-600. PubMed ID: 23590709
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
Fayek SA; Mantipisitkul W; Rasetto F; Munivenkatappa R; Barth RN; Philosophe B
HPB (Oxford); 2010 Dec; 12(10):657-63. PubMed ID: 21083790
[TBL] [Abstract][Full Text] [Related]
20. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
